These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1522236)

  • 1. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.
    Gozes I; Fridkin M
    J Clin Invest; 1992 Sep; 90(3):810-4. PubMed ID: 1522236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.
    Gozes I; Reshef A; Salah D; Rubinraut S; Fridkin M
    Endocrinology; 1994 May; 134(5):2121-5. PubMed ID: 8156912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats.
    Zhang MG; Shen ZJ; Zhang CM; Wu W; Gao PJ; Chen SW; Zhou WL
    BJU Int; 2011 Aug; 108(3):440-6. PubMed ID: 21166748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasoactive intestinal peptide and acetylcholine on penile erection in the rat in vivo.
    Suh JK; Mun KH; Cho CK; Shin HC; Kim YS; Park TC
    Int J Impot Res; 1995 Jun; 7(2):111-8. PubMed ID: 7496439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat.
    Shen ZJ; Wang H; Lu YL; Zhou XL; Chen SW; Chen ZD
    BJU Int; 2005 Apr; 95(6):890-4. PubMed ID: 15794804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal polypeptide (VIP) is not an androgen-dependent neuromediator of penile erection.
    Cormio L; Gesualdo L; Maiorano E; Bettocchi C; Palumbo F; Traficante A; Schena FP; Selvaggi FP
    Int J Impot Res; 2005; 17(1):23-6. PubMed ID: 15526009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study.
    Miller MA; Morgan RJ; Thompson CS; Mikhailidis DP; Jeremy JY
    Int J Impot Res; 1995 Jun; 7(2):91-100. PubMed ID: 7496446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
    McMahon CG
    Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of vasoactive intestinal peptide (VIP) as a humoral mediator of penile erectile function in the dog.
    Aoki H; Matsuzaka J; Yeh KH; Sato F; Fujioka T; Kubo T; Ohhori T; Yasuda N
    J Androl; 1994; 15(2):174-82. PubMed ID: 8056641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model.
    Kang KK; Ahn GJ; Shim HJ; Kwon JW
    Life Sci; 2004 Jul; 75(9):1075-83. PubMed ID: 15207655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intracavernous pharmacotherapy for organic impotence in the elderly].
    Richter S; Shalev M; Nissenkorn I
    Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
    Gozes I; Meltzer E; Rubinrout S; Brenneman DE; Fridkin M
    Endocrinology; 1989 Dec; 125(6):2945-9. PubMed ID: 2583049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erection: a combined in vivo and immunohistochemical study.
    Juenemann KP; Lue TF; Luo JA; Jadallah SA; Nunes LL; Tanagho EA
    J Urol; 1987 Oct; 138(4):871-7. PubMed ID: 2888903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on intracavernosal VIP levels during pharmacologically induced penile erections.
    Kiely EA; Blank MA; Bloom SR; Williams G
    Br J Urol; 1987 Apr; 59(4):334-9. PubMed ID: 2437991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an environmental anti-androgen on erectile function in an animal penile erection model.
    Brien SE; Heaton JP; Racz WJ; Adams MA
    J Urol; 2000 Apr; 163(4):1315-21. PubMed ID: 10737536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurotransmitters of penile erection other than vasoactive intestinal polypeptide. Physiologic data and therapeutic consequences].
    Adaikan PG; Lau LC; Vasatha KS; Susheela K; Ratnam SS
    J Urol (Paris); 1990; 96(1):15-8. PubMed ID: 1968931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives.
    Gressens P; Besse L; Robberecht P; Gozes I; Fridkin M; Evrard P
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1207-13. PubMed ID: 10027860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the studies of vasoactive intestinal polypeptide].
    Shen ZJ
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):483-5. PubMed ID: 16078660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavernous administration of SIN-1+VIP in an in vivo rabbit model for erectile function.
    Sazova O; Kadioğlu A; Gürkan L; Kayaarasi Z; Bross S; Manning M; Jünemann KP
    Int J Impot Res; 2002 Feb; 14(1):44-9. PubMed ID: 11896477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local pharmacotherapy for impotence.
    Riley AJ
    Br J Clin Pract; 1993; 47(3):118-9. PubMed ID: 8347433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.